Life-science company Invion (ASX:IVX) has taken a ‘significant’ step towards starting clinical trials by reaching a manufacturing milestone for its INV043 drug substance, used for the treatment of cancers.
The company says it has manufactured its lead candidate under a Good Manufacturing Practice (GMP)-compliant process.
Invion collaborated with IDT Australia (ASX:IDT), an Australian biopharmaceutical contract development and manufacturing organisation with more than 40 years of experience producing high-containment and high-potency Active Pharmaceutical Ingredients (API), to achieve this milestone.
Invion is focused on the global research and development of ‘Photosoft’ technology for the treatment of a range of cancers, atherosclerosis, and infectious diseases.
It holds the exclusive Australia and New Zealand license rights and exclusive distribution rights to Asia Pacific excluding China (other than Hong Kong, which is included in the Territory), Macau, Taiwan, Japan, and South Korea to the Photosoft technology for all cancer indications.
Invion is developing Photosoft technology as a novel next-generation Photodynamic Therapy (PDT). PDT uses non-toxic photosensitisers and light to selectively kill cancer cells and promote an anti-cancer immune response.
Less invasive than surgery and with minimal side effects, Invion says PDT offers an alternative treatment option aimed at achieving complete tumour regression and long-lasting remission.
Write to Adam Orlando at Mining.com.au